ChartMill · Sep 24, 2026
Unusual volume stocks in Thursday's session
Unusual volume stocks in Thursday's session
TL
NASDAQ · TLSI
TriSalus Life Sciences, Inc.
Healthcare · Medical - Devices
$4.38
Down-$0.11 (-2.51%)
Updated Oct 6, 2026, 9:57 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 247.45M
- P/E ratio
- -4.6
- Dividend yield
- 0.00%
- 52-week range
- $2.20 – $7.95
- Volume
- 132.71K
- Avg. volume
- 137.4K
Price performance · TLSI
TLSI price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
TLSI closed at $4.38 after 20 trading sessions, down 7.40% for the selected period.
- Last close
- $4.38
- Period change
- -7.40%
- Period low
- $4.15
- Period high
- $5.10
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $4.30 | $4.40 | $4.20 | $4.38 | 132.71K |
| Oct 2, 2026 | $4.22 | $4.47 | $4.042 | $4.32 | 145.38K |
| Oct 1, 2026 | $4.27 | $4.27 | $4.0191 | $4.15 | 273.18K |
| Sep 30, 2026 | $4.26 | $4.50 | $4.245 | $4.31 | 627.16K |
| Sep 29, 2026 | $4.36 | $4.42 | $4.17 | $4.25 | 186.37K |
| Sep 28, 2026 | $4.28 | $4.40 | $4.08 | $4.39 | 253.78K |
| Sep 25, 2026 | $4.57 | $4.62 | $4.32 | $4.34 | 351.41K |
| Sep 24, 2026 | $4.98 | $5.30 | $4.58 | $4.61 | 810.44K |
| Sep 23, 2026 | $5.78 | $5.83 | $4.92 | $5.00 | 2.6M |
| Sep 22, 2026 | $4.98 | $5.15 | $4.82 | $4.93 | 2.61M |
| Sep 21, 2026 | $5.14 | $5.22 | $4.92 | $4.98 | 161.23K |
| Sep 18, 2026 | $4.91 | $5.11 | $4.83 | $5.10 | 606.96K |
| Sep 17, 2026 | $5.03 | $5.05 | $4.86 | $4.90 | 114.31K |
| Sep 16, 2026 | $4.82 | $4.95 | $4.47 | $4.93 | 156.51K |
| Sep 15, 2026 | $4.76 | $4.79 | $4.53 | $4.78 | 162.5K |
| Sep 14, 2026 | $4.63 | $4.845 | $4.5823 | $4.77 | 101.31K |
| Sep 11, 2026 | $4.79 | $4.855 | $4.59 | $4.665 | 100.26K |
| Sep 10, 2026 | $4.71 | $4.80 | $4.65 | $4.70 | 68.47K |
| Sep 9, 2026 | $4.90 | $4.91 | $4.68 | $4.76 | 119.35K |
| Sep 8, 2026 | $4.94 | $4.99 | $4.48 | $4.73 | 129.3K |
Latest TLSI news
The latest Smart Investors Daily articles mentioning TLSI.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TLSI research
Overview
Company profile and research snapshot.
Company profile
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $10.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 9, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Lake Street | Buy | — |
| Mar 9, 2026 | Canaccord Genuity | Buy | — |
| Mar 6, 2026 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 23, 2026
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
TriSalus Life Sciences secured FDA clearance for its TriNav Advance device, but shares face critical resistance levels amid a recent slide.
Yahoo · Sep 23, 2026
TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance
TriSalus Life Sciences (NASDAQ:TLSI) shares rose 15. 6% in pre-market trading after the company announced that the U.
Benzinga · Sep 23, 2026
Microsoft To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for Meta, Microsoft, Valero and others; Microsoft upgraded to Buy, while KB Home and RTX targets fell.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
